

BioMmune Technologies Inc.

1780 - 400 Burrard Street
Vancouver, BC, V6C 3A6
Telephone: (604) 273-6955/ Fax: (604) 273-1497

MANAGEMENT INFORMATION CIRCULAR

As at October 1, 2014 (*unless otherwise indicated*)

This Management Information Circular (“Circular”) is furnished in connection with the solicitation of proxies by the management of BioMmune Technologies Inc. (the “Company”) for use at the Annual and Special Meeting of the holders (the “Shareholders”) of common shares (the “Common Shares”) of the Company to be held at 1780 - 400 Burrard Street, Vancouver, BC V6C 3A6, on October 30, 2014 at 10:00 a.m. (Vancouver Time) and at any adjournment thereof (the “Meeting”), for the purposes set forth in the notice of the Meeting (the “Notice”) accompanying this Circular.

In this document, we, us, our, bioMmune and the Company mean bioMmune Technologies Inc. You, your, and bioMmune Shareholder mean registered holders of common shares of bioMmune Technologies Inc. “Common Shares” means common shares without par value in the capital of the Company. “Beneficial Shareholders” means shareholders who do not hold Common Shares in their own name and “intermediaries” refers to brokers, investment firms, clearing houses and similar entities that own securities on behalf of Beneficial Shareholders. All dollar amounts referred herein, unless otherwise indicated, are expressed in Canadian dollars.

The information contained in this Circular is given as of October 1, 2014 (the “Circular Date”) except where otherwise indicated.

INFORMATION REGARDING PROXIES AND VOTING AT THE MEETING

Solicitation of Proxies

The solicitation of proxies will be primarily by mail, but may be solicited by way of telephone, facsimile or other means of communication to be made without special compensation by the directors, officers and regular employees of the Company. Costs associated with the solicitation of proxies will be borne by the Company. We have arranged for intermediaries to forward the meeting materials to beneficial owners of the Common Shares held of record by those intermediaries and we may reimburse the intermediaries for their reasonable fees and disbursements in that regard.

No person has been authorized to give any information or to make any representation other than as contained in this Circular in connection with the solicitation of proxies. If given or made, such information or representations must not be relied upon as having been authorized by the Company. The delivery of this Circular shall not create, under any circumstances, any implication that there has been no in the information set forth herein since the date of this Circular. This Circular does not constitute the solicitation of a proxy by anyone in any jurisdiction in which such solicitation is not authorized, or in which the person making such solicitation is not qualified to do so, or to anyone to whom it is unlawful to make such an offer of solicitation.

Appointment of Proxyholders

A shareholder is entitled to one vote for each Common Shares that such Shareholder holds on the Record Date of September 26, 2014 on the resolutions to be voted upon at the Meeting, and any other matter to come before the Meeting. The persons named in the accompanying form of proxy (the “**Proxy**”) are officers and/or directors of the Company (“**Management Proxyholders**”).

A Shareholder has the right to appoint a person (who need not be a shareholder) to attend and act for him or her on his or her behalf at the Meeting other than Management Proxyholders. To exercise this right the Shareholder must strike out the names of Management Proxyholders and insert the name of his or her nominee in the blank space provided in the Proxy, or complete another suitable form of proxy. Such Shareholder should notify the nominee of the appointment, obtain the nominee’s consent to act as proxyholder and should provide instructions to the nominee on how the Shareholder’s shares should be voted. The nominee should bring the personal identification to the Meeting.

If your common shares are held in physical form (i.e. paper form) and are registered in your name, then you are a registered shareholder (“Registered Shareholder”). However, if, like most shareholders, you keep your Common Shares in a brokerage account, then you are a beneficial shareholder (“Beneficial Shareholder”). The manner for voting is different for Registered and Beneficial Shareholders. The instructions below should be read carefully by all Shareholders.

Signing of Proxy

The instrument of proxy must be dated and executed by the Shareholder or the Shareholder’s duly appointed attorney authorized in writing or, if the Shareholder is a corporation, by a duly authorized officer whose title must be indicated. An instrument of proxy signed by a person acting as attorney or in some other representative capacity should indicate that person’s capacity (following his or her signature) and should be accompanied by the appropriate instrument evidencing qualification and authority to act (unless such instrument has previously been filed with the Company).

Revocability of Proxy

A Shareholder who has validly given a proxy may revoke it for any matter upon which a vote has not already been cast by the proxyholder appointed therein. In addition to revocation in any manner permitted by law, an instrument of proxy may be revoked by an instrument in writing executed by the Shareholder or by his or her duly authorized attorney, or, if the Shareholder is a corporation, under its corporate seal by a duly authorized officer or attorney of the corporation and delivered to either the Company’s transfer agent, Computershare Investor Services Inc. at 8th Floor, 100 University Avenue, Toronto, Ontario M5J 2Y1, at any time up to and including the last business day preceding the date of the Meeting, or any adjournment thereof at which the instrument of proxy is to be used, or deposited with the Chairman of the Meeting on the day of the Meeting, or any adjournment thereof.

In addition, a Shareholder, or, if the Shareholder is a corporation, a duly authorized representative of the corporation, submit a subsequent proxy in accordance with the foregoing procedure or may attend the Meeting in person, revoke the instrument of proxy by indicating such intention to the Chairman of the Meeting before the instrument of proxy is exercised, and vote in person.

A revocation of a proxy will not affect a matter on which a vote is taken before the revocation.

Voting of Proxies and Exercise of Discretion by Proxyholders

All Common Shares represented at the Meeting by properly executed proxies will be voted on any ballot that may be called for and, where a choice with respect to any matter to be acted upon has been specified in the instrument of proxy, the Common Shares represented by the instrument of proxy will be voted in accordance with such instructions. The Management Proxyholders named in the accompanying instrument of proxy will vote or withhold from voting the Common Shares in respect of which they are appointed in accordance with the direction of the Shareholder appointing him or her on any ballot that may be called for at the Meeting.

In the absence of such direction with respect to a matter to be acted upon, the Proxy confers discretionary authority with respect to that matter upon the appointed Proxyholders named in the form of Proxy. It is intended that the Management Proxyholders will vote such Common Shares IN FAVOUR of each matter identified in the Proxy.

If any amendment or variation to the matters identified in the Notice are properly brought before the Meeting or any further or other business is properly brought before the Meeting, the accompanying instrument of proxy confers discretionary authority to vote on such amendments or variations or such other business according to the best judgment of the appointed proxyholder. As at the Circular Date, the management of the Company knows of no such amendment, variation or other matter to come before the Meeting other than the matters referred to in the accompanying Notice.

In the case of abstention from, or withholding of, the voting of the Common Shares on any matter, the Common Shares that are subject to the abstention or withholding will be counted for determination of a quorum, but will not be counted as affirmative or negative on the matter to be voted upon.

Registered Shareholders

Registered Shareholders are entitled to vote at the Meeting. Registered Shareholders may wish to vote by proxy whether or not they are able to attend the Meeting in person. Registered Shareholders electing to submit a proxy may do so by:

- (a) completing, dating and signing the enclosed form of proxy and returning it to the Company's transfer agent, Computershare Investor Services Inc. by fax within North America at 1-866-249-7775, outside North America at (416) 263-9524, or by mail or hand delivery at 8th Floor, 100 University Avenue, Toronto, Ontario M5J 2Y1;
- (b) using a touch-tone phone to transmit voting choices to a toll free number at 1-866-732-8683 and following the instructions on the voice response system by providing the holders' account number and the proxy access number. Instructions are then conveyed by use of the touchtone selections over the telephone; or
- (c) using the internet through the website of the Company's transfer agent at www.investorvote.com. Registered Shareholders must follow the instructions that appear on the screen and refer to the enclosed proxy form for the holder's account number and the proxy access number;

in all cases ensuring that the proxy is received at least 48 hours (excluding Saturdays, Sundays and holidays) before the time of the Meeting or any adjournment thereof at which the proxy is to be used.

Voting by Non-Registered Shareholders

The following information is of significant importance to Shareholders who do not hold Common Shares in their own name. Beneficial Shareholders should note that the only proxies that can be recognized and acted upon at the Meeting are those deposited by Registered Shareholders (those whose names appear on the records of the Company as the registered holders of Common Shares).

If Common Shares are listed in an account statement provided to a Shareholder by a broker, then in almost all cases those Common Shares will not be registered in the shareholder's name on the records of the Company. Such Common Shares will more likely be registered under the names of the Shareholder's broker or an agent of that broker. In the United States, the vast majority of such Common Shares are registered under the name of Cede & Co. as nominee for The Depository Trust Company (which acts as depository for many U.S. brokerage firms and custodian banks), and in Canada, under the name of CDS & Co. (the registration name for The Canadian Depository for Securities Limited, which acts as nominee for many Canadian brokerage firms). Beneficial Shareholders should ensure that instructions respecting the voting of their Common Shares are communicated to the appropriate person well in advance of the Meeting.

The Company does not have access to names of Beneficial Shareholders. Intermediaries are required to seek voting instructions from Beneficial Shareholders in advance of shareholders' meetings. Every intermediary has its own mailing procedures and provides its own return instructions to clients, which should be carefully followed by Beneficial Shareholders in order to ensure that their Common Shares are voted at the Meeting.

There are two kinds of Beneficial Shareholders - those who object to their name being made known to the issuers of securities which they own (called OBOs for Objecting Beneficial Owners) and those who do not object to the issuers of the securities they own knowing who they are (called NOBOs for Non-Objecting Beneficial Owners).

The Company is taking advantage of the provisions of National Instrument 54-101 that permit it to directly deliver proxy-related materials to its NOBOs. As a result NOBOs can expect to receive a scannable Voting Instruction Form (VIF) from the Company's transfer agent, Computershare Investor Services Inc. ("**Computershare**"). These VIFs are to be completed and returned to Computershare in the envelope provided or by facsimile. In addition, Computershare provides both telephone voting and internet voting as described on the VIF itself which contain complete instructions. Computershare will tabulate the results of the VIFs received from NOBOs and will provide appropriate instructions at the Meeting with respect to the shares represented by the VIFs they receive. These securityholder materials are being sent to both registered and non-registered owners of the securities of the Company. If you are a non-registered owner, and the Company or its agent has sent these materials directly to you, your name and address and information about your holdings of securities, have been obtained in accordance with applicable securities regulatory requirements from the intermediary holding on your behalf.

By choosing to send these materials to you directly, the Company (and not the intermediary holding on your behalf) has assumed responsibility for (i) delivering these materials to you, and (ii) executing your proper voting instructions. Please return your voting instructions as specified in your request for voting instructions.

Intermediaries are required to forward the Circular to OBOs unless the OBO has waived the right to receive them. Very often, Intermediaries will use service companies to forward the Circular to OBOs. Beneficial Shareholders who are OBOs should follow the instructions of their intermediary carefully to

ensure that their Common Shares are voted at the Meeting. The form of proxy supplied to you by your broker will be similar to the proxy provided to Registered Shareholders by the Company. However, its purpose is limited to instructing the intermediary on how to vote on your behalf. Most brokers now delegate responsibility for obtaining instructions from clients to Broadridge Investor Communications Inc. (“**Broadridge**”) in the United States and in Canada. Broadridge mails a VIF in lieu of a proxy provided by the Company. The VIF will name the same persons as the Company’s Proxy to represent you at the Meeting. You have the right to appoint a person (who need not be a Beneficial Shareholder of the Company), other than the persons designated in the VIF, to represent you at the Meeting. To exercise this right, you should insert the name of the desired representative in the blank space provided in the VIF. The completed VIF must then be returned to Broadridge by mail or facsimile or given to Broadridge by phone or over the internet, in accordance with Broadridge’s instructions. Broadridge then tabulates the results of all instructions received and provides appropriate instructions respecting the voting of Common Shares to be represented at the Meeting.

If you receive a VIF from Broadridge, you cannot use it to vote Common Shares directly at the Meeting - the VIF must be completed and returned to Broadridge, in accordance with its instructions, well in advance of the Meeting in order to (a) have your Common Shares voted as per your instructions, or (b) to have any alternate representative chosen by you duly appointed to attend and vote your Common Shares at the Meeting.

Alternatively, you can request in writing that your broker send you a legal proxy which would enable you, or a person designated by you, to attend at the Meeting and vote your Common Shares.

Although as a Beneficial Shareholder you may not be recognized directly at the Meeting for the purposes of voting Common Shares registered in the name of your broker, you, or a person designated by you, may attend at the Meeting as proxyholder for your broker and vote your Common Shares in that capacity. If you wish to attend at the Meeting and indirectly vote your Common Shares as proxyholder for your broker, or have a person designated by you do so, you should enter your own name, or the name of the person you wish to designate, in the blank space on the voting instruction form provided to you and return the same to your broker in accordance with the instructions provided by such broker, well in advance of the Meeting. All references to shareholders in this Circular are to Registered Shareholders, unless specifically stated otherwise.

INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON

Except as disclosed elsewhere in this Circular, none of the directors or officers of the Company, nor any person who has held such a position since the beginning of the last completed financial year of the Company, nor any proposed nominee for election as a director of the Company, nor any associate or affiliate of any of the foregoing persons, has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise in any matter to be acted on, other than the election of directors, the approval of the 10% rolling Option Plan, as such persons are eligible to participate in the Option Plan and as set out herein.

VOTING SECURITIES AND PRINCIPAL HOLDERS OF VOTING SECURITIES

Voting Shares and Record Date

Each Registered Shareholder at the close of business on September 26, 2014 (the “**Record Date**”) is entitled to receive notice of, and to attend and vote at and such Shareholders are encouraged to participate in the Meeting and are urged to vote on matters to be considered in person or by proxy.

The authorized share capital of the Company consists of an unlimited number of Common Shares. As at the Record Date, the Company had 24,673,417 Common Shares issued and outstanding. No group of shareholders has the right to elect a specified number of directors, nor are there cumulative or similar voting rights attached to the Common Shares.

The quorum for the transaction of business at the Meeting is one shareholder, or one proxyholder representing shareholders who, in the aggregate, holds at least one-twentieth of the issued Common Shares entitled to be voted at the meeting.

Principal Holders of Voting Securities

To the knowledge of the directors and executive officers of the Company, as at the Circular Date, none of the Shareholders beneficially own or control or direct, directly or indirectly, voting securities carrying 10% or more of the voting rights attached to any class of voting securities of the Company.

FINANCIAL STATEMENTS

The audited financial statements of the Company for the fiscal period ended November 30, 2013 and report of the auditor thereon will be placed before the Meeting. These documents have been filed with the securities commissions or similar regulatory authorities in British Columbia, Alberta and Ontario. Copies of the documents may be obtained by a Shareholder upon request without charge from the Company at Suite 1780 - 400 Burrard Street, Vancouver, British Columbia V6C 3A6, or by telephone: (604) 688-6775. These documents are also available through the internet on SEDAR at www.sedar.com.

APPOINTMENT OF AUDITOR

Smythe Ratcliffe LLP, of 700- 355 Burrard Street, Vancouver, BC, V6C 2G8 will be nominated at the Meeting for reappointment as auditor of the Company. Smythe Ratcliffe LLP has been the auditor of the Company since January 28, 2012.

Unless otherwise instructed, the Management Proxyholders in the accompanying instrument of proxy intend to vote FOR the resolution to re-appointment of Smythe Ratcliffe LLP as the auditors of the Company to hold office for the ensuing year at remuneration to be fixed by the Board of Directors.

NUMBER OF DIRECTORS

At the Meeting, Shareholders will be asked to pass an ordinary resolution to set the number of directors of the Company for the ensuing year at four (4).

Management recommends the approval of the resolution to set the number of directors of the Company at four. Unless otherwise instructed, the Management Proxyholders in the accompanying instrument of proxy intend to vote FOR the resolution to set the number of directors of the Company at four.

ELECTION OF DIRECTORS

The term of office of each of the present four directors will expire at the Meeting. **The four persons named below will be presented for election at the Meeting as management's nominees and unless otherwise directed, the Management Proxyholders, if named as proxyholder for Shareholders, will vote FOR the election of these nominees.** Management does not contemplate that any of these nominees will be unable to serve as a director. Each director elected will hold office until the next annual

meeting of the Company or until a successor is duly elected or appointed or unless his office is earlier vacated in accordance with the Articles of the Company, or with the provisions of the *Business Corporations Act* (British Columbia). No class of shareholders of the Company has the right to elect a specified number of directors or to cumulate their votes for directors.

Summary of Director Biographical Information and Security Holdings

The following table sets forth the name of each person nominated for election as a director, the province of residence for each nominee, the period during which any such person has been a director of the Company, the principal occupation at the present time and during the preceding five years of such nominee, and the number and percentage of Common Shares beneficially owned, or controlled or directed, directly or indirectly, by the nominee, as at the Circular Date.

Name of Nominee, Current Position with the Company and Province and Country of Residence ⁽¹⁾	Period as a Director of the Company	Principal Occupation During Past 5 Years	Number and Percentage of Common Shares Owned or Controlled ⁽¹⁾
Robin Hutchison ⁽²⁾ <i>Surrey, BC</i> Executive Chairman and Director	January 28, 2011	BiOasis Technologies Inc., Director and CEO	1,900,000 7.7%
J. Michael Hutchison, Q.C. ^{(2) (3)} <i>Victoria, BC</i> Director	May 28, 2013	Smith Hutchison Law Corporation, Principal	1,825,000 7.40%
Craig D. Thomas ⁽²⁾ <i>West Vancouver, BC</i> Director	May 28, 2013	Thomas Rondeau LLP, Associate Counsel	Nil
Karoly Nikolich <i>Emerald Hills, California, USA</i> Director	September 24, 2013	Circuit Therapeutics Inc., President Amnestix Inc., CEO	Nil

Notes:

- (1) The information as to country of residence, principal occupation and Common Shares owned or over which a director exercises control or direction has been confirmed by the respective directors individually;
- (2) Member of the Audit Committee; and
- (3) 1,325,000 of these common shares are held by RBH Consulting Inc., a private company owned by Hutchison Family Trust. Hutchison Family Trust is a discretionary trust and Mr. Michael Hutchison is its sole trustee.

Corporate Cease Trade Orders or Bankruptcies

Other than as disclosed below, to the knowledge of the Company, none of the proposed directors of the Company is, as at the date hereof, or has been, within the previous 10 years, a director, chief executive officer or chief financial officer of any company (including the Company) that, (i) was subject to a cease trade or similar order that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer, or (ii) was subject to a cease trade or similar order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.

Mr. Craig D. Thomas was a director and President of Golden Raven Resources Ltd., a reporting issuer that had a cease trade order issued by the British Columbia Securities Commission on February 7, 2006

and amended on August 23, 2006 and the Alberta Securities Commission on September 13, 2006 for the failure to file financial statements; a director of West Coast Forest Products Ltd., a reporting issuer that had a cease trade order issued by the British Columbia Securities Commission on September 6, 2005, a cease trade order issued on October 28, 2005 by the Ontario Securities Commission, and a cease trade order issued on December 16, 2005 by the Alberta Securities Commission for failure to file financial statements; and a director of Maxxcapp Corporation, a reporting issuer that had cease trade orders issued by the British Columbia Securities Commission on May 9, 2007 and by the Alberta Securities Commission on August 24, 2007 for failure to file financial statements. The cease trade orders mentioned above are still in effect and Golden Raven Resources Ltd. and Maxxcapp Corporation have since been delisted.

To the knowledge of the Company, none of the proposed directors of the Company is, as at the date hereof, or has been, within the previous 10 years, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

Penalties or Sanctions

To the knowledge of the Company, none of the proposed directors of the Company has been subject to (a) any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or (b) any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable securityholder in deciding whether to vote for a proposed director.

Personal Bankruptcies

To the knowledge of the Company, none of the proposed directors of the Company has, within the 10 years before the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director.

Several directors of the Company also serve as directors of one or more other companies. It may occur from time to time that as a consequence of such director's activity in the related industry and serving on such other boards that a director may become aware of potential opportunities which are of interest to more than one of the companies on whose boards that person serves. Accordingly, situations may arise in the ordinary course which involve a director in an actual or potential conflict of interest as well as issues in connection with the general obligation of a director to make corporate opportunities available to the company on which the director serves. In all such events, any director is required to disclose a financial interest in a contract or transaction by virtue of office, employment or security holdings or other such interest in another company or in a property interest under consideration by the Board of Directors, and is obliged to abstain from voting as a director of the Company in respect of any transaction involving that other company or in respect of any property in which an interest is held by him. The directors will use their best business judgment to help avoid situations where conflicts or corporate opportunity issues might arise and they must at all times fulfil their duties to act honestly and in the best interests of the Company.

Biographies of Directors

The following information as to principal occupation, business or employment, within the past five years is not within the knowledge of the Company's management and has been furnished by the respective nominees.

Robin (Rob) B. Hutchison (58), Executive Chairman and Director

Mr. Hutchison serves as a director and the CEO of BiOasis Technologies Inc., a publicly-traded biopharmaceutical company focused on developing and commercializing pharmaceutical products and diagnostic technologies. He is also a member of the boards of directors of Golden Goliath Resources Ltd., a publicly-traded company; and has served on the board of directors of other publicly-traded companies in the past. Mr. Hutchison has more than 23 years of experience in the field of information technology.

Craig D. Thomas (61), director

Craig D. Thomas, is a barrister and solicitor and an associate counsel of the law firm of Thomas, Rondeau LLP specializing in the practice of corporate and securities law matters, including structuring and implementation of corporate financing transactions, public and private securities offerings, mergers and acquisitions, registration, reporting and compliance matters. Mr. Thomas earned his undergraduate degree in 1975 from Harvard College and his Bachelor of Laws degree in 1978 from the University of Alberta. Mr. Thomas has practiced law in British Columbia since 1979. Mr. Thomas has served as an officer and director of numerous publicly listed companies.

J. Michael Hutchison Q.C. (70), director

J. Michael Hutchison Q.C. is a lawyer in private practice with an office in Victoria, for 42 years. He practices primarily in the areas of corporate commercial law, administrative law and civil litigation. He was appointed Queens' Counsel in 1985. Mr. Hutchison has been and is a member of the board of directors in various private corporations, primarily start-up technology-related companies. He was elected a School Trustee for four years, and was a member of and Chairman of the Board of Governors of Camosun College in Victoria, B.C. He has served as the external counsel for the University of Victoria and was general counsel to the Board of Examiners in Optometry of British Columbia for more than thirty years. Currently, he is counsel to and a member of the board of directors of the Victoria Heart Institute Foundation and serves as a director of BiOasis Technologies Inc., a publicly-traded biopharmaceutical company.

Karoly Nikolich (66), director

Dr. Nikolich is a renowned biotechnology expert with an extensive track record within this industry. Highlights include: former head of the Neuroscience Program at Genentech Inc.; Adjunct Professor, Neuroscience, USC, Los Angeles, CA; Vice President, Research, Lynx Therapeutics, Inc. Hayward, CA and Director (Supervisory Board) BASF-LYNX Bioscience AG, Heidelberg; former CEO, Amnestix, Inc., and Neurofluidics, Inc., Burlingame, CA; Executive Director, Neuroscience Institute at Stanford (NIS), Stanford University Medical School; Founder, Chief Executive Officer, and Director (Board member) AGY Therapeutics, Inc., South San Francisco, CA; and currently Dr. Nikolich is Founder and President of Circuit Therapeutics, Inc., and a consulting Professor at Stanford University Medical School. Along with an extensive professional history, Dr. Nikolich has been an author on over 120 scientific and review publications.

APPROVAL OF STOCK OPTION PLAN

Annual Approval of Stock Option Plan

At the Meeting, the Shareholders will be asked to consider and, if deemed advisable, vote in favour of a resolution ratifying and approving the existing stock option plan (the “**Option Plan**”). The Option Plan is a “rolling” stock option plan whereby a maximum of 10% of the issued Common Shares of the Company, from time to time, may be reserved for issuance under the Option Plan. As the Company’s Option Plan is a “rolling” plan, the policies of the TSXV require that the Company seek shareholder approval of the Option Plan annually.

Outstanding Options

As at the Circular Date, there are 24,673,417 Common Shares issued and outstanding, 10% of which is 2,467,341 Common Shares. At the Circular Date, there are options outstanding to purchase an aggregate of 1,850,000 Common Shares, and accordingly there are 617,341 options available for granting under the Option Plan.

Material Terms of the Stock Option Plan

The Option Plan is administered by the Board of Directors. A full copy of the Option Plan is available to shareholders of the Company upon request and will be available at the Meeting.

The following is a brief description of the principal terms of the Option Plan, which description is qualified in its entirety by the terms of the Option Plan:

1. The aggregate number of common shares which may be issued and sold under the Option Plan will not exceed 10% of the issued and outstanding shares at the time of grant of any option under the Option Plan.
2. The option price of any common shares in respect of which an option may be granted shall be fixed by the Board provided that the minimum exercise price shall not be less than the market price of the common shares at the time the option is granted, less the discounts permitted by the Exchange.
3. Stock options under the Option Plan may be granted by the Board of Directors to directors, senior officers, employees or consultants of the Corporation, collectively known as the "Participants".
4. Options granted under the Option Plan are exercisable over a period not exceeding ten years, provided that notwithstanding the foregoing, if the term of any Option granted under the Option Plan ends on a day occurring during a blackout period (being the period imposed by the Company during which insiders are prohibited from trading in the securities of the Company) or within nine business days thereafter, such expiry date of the Option shall be automatically extended without any further act or formality to that date which is the tenth business day after the end of the blackout period, such tenth business day to be considered the expiry date for such Option for all purposes under the Option Plan.
5. Subject to any vesting restrictions imposed by the TSXV, the Board of Directors may, in its sole discretion, determine the time during which options shall vest and the method of vesting, or that no vesting restriction shall exist.

6. no single Participant may be granted options to purchase a number of common shares of the Company equaling more than 5% of the issued Common Shares of the Company in any one twelve-month period unless the Company has obtained disinterested shareholder approval in respect of such grant and meets applicable TSXV requirements;
7. Options shall not be granted if the exercise thereof would result in the issuance of more than 2% of the issued Common Shares of the Company in any twelve-month period to any one consultant of the Company (or any of its subsidiaries); and
8. Options shall not be granted if the exercise thereof would result in the issuance of more than 2% of the issued Common Shares of the Company in any twelve month period to persons employed to provide investor relations activities. Options granted to consultants performing investor relations activities will contain vesting provisions such that vesting occurs over at least 12 months with no more than $\frac{1}{4}$ of the options vesting in any 3 month period.
9. No Options can be granted under the Option Plan if the Company is on notice from the TSXV to transfer its listed shares to the NEX or while the Company's shares trade on the NEX.
10. If a Participant receives options while the Company is classified as a Capital Pool Company by the TSXV and the Participant ceases to be a director, officer consultant or employee of the Company or its subsidiaries, for any reason (other than death), such Participant may exercise his option to the extent that the Participant was entitled to exercise it at the date of such cessation, provided, that such exercise must occur prior to the later of 12 months after the completion of a qualifying transaction and 90 days after the person ceases to be a director, officer, consultant or employee of the Company.
11. If a Participant ceases to be a technical consultant/non-technical consultant or employee of the Company or any of its subsidiaries as a result of retirement, resignation or termination without cause other than as set out in subsection 9 above, such Participant shall have the right for a period of 90 days (or until the normal expiry date of the option rights of such Participant, if earlier) from the date of ceasing to be a technical consultant/non-technical consultant or employee to exercise all unexercised option rights of that Participant under the Option Plan to the extent they were exercisable on the date of ceasing to be a technical consultant/non-technical consultant or employee; provided that if such Participant was engaged in investor relations activities, such exercise must occur within 30 days after the cessation of the Participant's services to the Company (subject to extension at the discretion of the Board).
12. If a Participant ceases to be a director or officer of the Company or any of its subsidiaries as a result of retirement, resignation or termination without cause other than as set out in subsection 9 above, subject to the discretion of the Board of Directors, such Participant shall have the right for a period of one year (or until the normal expiry date of the option rights of such Participant, if earlier) from the date of ceasing to be a director or officer to exercise all unexercised option rights of that Participant under the Option Plan to the extent they were exercisable on the date of ceasing to be a director or officer.
13. No right or interest of any Participant in or under the Option Plan is assignable or transferable, in whole or in part, either directly or by operation of law or otherwise in any manner except by bequeath or the laws of descent and distribution.
14. In the event an Option granted under the Option Plan expires unexercised or is terminated by reason of dismissal of the Participant for cause or is otherwise lawfully cancelled prior to exercise

of the option, the option shares that were issuable thereunder will be returned to the Option Plan and will be eligible for reissuance.

15. Subject to applicable approval of the TSXV, the Board of Directors may, at any time, suspend or terminate the Option Plan, amend or revise the terms of the Option Plan; provided that no such amendment or revision shall result in a material adverse change to the terms of any Options theretofore granted under the Option Plan, unless shareholder approval, or disinterested shareholder approval, as the case may be, is obtained for such amendment or revision.

Shareholder Approval

At the Meeting, Shareholders will be asked to consider and vote on the following ordinary resolution, with or without variation:

“BE IT RESOLVED as an ordinary resolution of the shareholders that:

- (1) the 10% rolling Option Plan of the Company dated for reference March 15, 2012 be and is hereby ratified and approved for continuation until the next annual meeting of the Company, subject to regulatory approval;
- (2) to the extent permitted by law, the Company be authorized to abandon or amend all or any part of the Option Plan if the Board of Directors deems is appropriate and in the best interests of the Company to do so;
- (3) the Board of Directors, by resolution, be authorized to make such amendments to the Option Plan, from time to time, as may, in its discretion, be considered appropriate, provided always that such amendments be subject to the approval of all applicable regulatory authorities; and
- (4) any one or more of the directors or senior officers of the Company be and is hereby authorized and directed to perform all such acts, deeds and things and execute, under the seal of the Company, or otherwise, all such documents and other writings, as may be required to give effect to the true intent of this resolution.”

The Board of Directors believes that passing the above resolution is in the best interests of the Company, and accordingly recommends that you vote in favour of the resolution.

Unless otherwise instructed, the Management Proxyholders in the accompanying instrument of proxy intend to vote FOR the resolution to approve the Option Plan.

STATEMENT OF EXECUTIVE COMPENSATION

In this section, Named Executive Officer (“NEO”) means the Chief Executive Officer of the Company (“CEO”), the Chief Financial Officer of the Company (“CFO”), each of the Company’s three most highly compensated executive officers, or the three most highly compensated individuals acting in a similar capacity, other than the CEO and CFO, who were serving as executive officers at November 30, 2013 and whose total compensation exceeded \$150,000, as well as any additional individuals for whom disclosure would have been provided except that the individual was not serving as a NEO of the Company at November 30, 2013.

For the most recently completed financial year that ended November 30, 2013, the Company had two NEO. Mr. John Morgan served as the Company’s Chief Executive Officer and Mr. Kenneth Churchill as the Company’s Chief Financial Officer and Corporate Secretary until May 28, 2013. On May 28, 2013

the Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4 of the TSXV), and Messrs. Morgan and Churchill resigned as directors and officers of the Company. Reinhard Gabathuler was appointed the President and Chief Executive Officer, Judi Dalling was appointed the Chief Financial Officer, Robin Hutchison was appointed Executive Chairman, and Craig D. Thomas and J. Michael Hutchison, Q.C. were appointed to the Board of Directors of the Company. Mr. Karoly Nikolich was appointed to the Company's Board of Directors on September 24, 2013.

Compensation Discussion and Analysis

The Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4) on May 28, 2013 and prior to that the Company's NEOs were not paid any compensation, as the Policy 2.4 prohibits directors and officers from receiving remuneration (other than incentive stock options) while the Company is a capital pool company.

Given the Company's status as an early-stage company, the Board of Directors does not feel that a compensation committee is required to evaluate compensation. The Board reviews and approves compensation paid to the Company's Named Executive Officers.

Compensation objectives include attracting and retaining highly-qualified individuals, creating among directors, officers, consultants and employees, a corporate environment which will align their interests with those of the shareholder and ensuring competitive compensation that is also affordable for the Company.

The compensation program is designed to provide competitive levels of compensation. The Company recognizes the need to provide a total compensation package that will attract and retain qualified and experienced executives as well as align the compensation level of each executive to that executive's level of responsibility. In general, the Company's Named Executive Officers may receive compensation that is comprised of three components: (a) salary, wages or contractor payments; (b) stock option grants; and (c) bonuses.

The Company has not begun to market any product or to generate revenues. As a result, the use of traditional performance standards, such as corporate profitability, is not considered by the Company to be appropriate in the evaluation of the performance of the NEOs. The salaries are set on a basis of a review and comparison of salaries paid to executives at similar companies.

Stock option grants are designed to reward the Named Executive Officers for success on a similar basis as the shareholders of the Company, although the level of reward provided by a particular stock option grant is dependent upon the volatility of the stock market.

Bonuses paid to the Named Executive Officers are allocated on an individual basis and are based on review by the Board of Directors of the work planned during the year and the work achieved during the year, including work related to mineral exploration, administration, financing, shareholder relations and overall performance. The bonuses are paid to reward work done above the base level of expectations set by the base salary, wages or contractor payments.

The Company does not have a share-based award incentive plan.

Restrictions on Purchase of Financial Instruments

Although the Company has not adopted a formal policy forbidding an NEO or director from purchasing financial instruments that are designed to hedge or offset a decrease in market value of equity securities

granted as compensation or held, directly or indirectly, by the NEO or director, the Company is not aware of any NEO or director having entered into this type of transaction.

Option-based Awards

The Company established the Option Plan in order to attract and retain directors, executive officers and employees, who will be motivated to work towards ensuring the success of the Company. The Board of Directors has full and complete authority to interpret the Option Plan, to establish applicable rules and regulation applying to it and to make all other determinations necessary or useful for the administration of the Option Plan, provided that such interpretation, rules, regulations and determinations are consistent with the rules of all stock exchanges on which the Company's securities are then traded and with all relevant securities legislation. See "Approval of Stock Option Plan" above for a description of the material terms of the Option Plan.

Individuals eligible to participate under the Option Plan will be determined by the Board of Directors in accordance with the rules of the stock exchanges on which the Company's securities are then traded and with applicable securities laws. Stock options may be granted to any director, officer, employee, or consultant of the Company, taking into consideration their contribution to the success of the Company and any other factor which the Board of Directors may deem proper and relevant. The exercise price of any options must be set in accordance with applicable stock exchange policies and the term of any option may not exceed ten years so long as the Company is listed on the TSXV. The Board of Directors designates, at its discretion, the individuals to whom stock options are granted under the Option Plan and determines the number of Common Shares covered by each of such options, the grant date, the exercise price of each option, the expiry date, the vesting schedule and any other matter relating thereto, in each case in accordance with the applicable rules and regulations of the regulatory authorities. The Board of Directors takes into account previous grants of options when considering new grants.

Summary Compensation Table

The following table and notes thereto set out information concerning the compensation paid to NEOs of the Company during the financial year ended November 30, 2013:

Name and Principal Position	Year	Annual Compensation					Total Compensation (\$)
		Salary (\$)	Option-based Awards ⁽¹⁾ (\$)	Non-equity incentive plan compensation (\$)	Other Compensation (\$)	Pension Value (\$)	
John Morgan CEO ⁽²⁾	2013	Nil	Nil	Nil	Nil	Nil	Nil
	2012	Nil	15,709	Nil	Nil	Nil	15,709
	2011	Nil	Nil	Nil	Nil	Nil	Nil
Kenneth Churchill CFO and Corporate Secretary ⁽²⁾	2013	Nil	Nil	Nil	Nil	Nil	Nil
	2012	Nil	15,709	Nil	Nil	Nil	15,709
	2011	Nil	Nil	Nil	Nil	Nil	Nil
Reinhard Gabathuler President and CEO ⁽³⁾	2013	30,000	16,892	Nil	Nil	Nil	46,892
Judi Dalling, CFO and Corporate Secretary ⁽⁴⁾	2013	32,500	14,766	Nil	Nil	Nil	47,266

Notes:

- The grant date fair value of these options would have been calculated in accordance with Section 3870 of the CICA Handbook (accounting fair value) using the Black-Scholes model. The Black-Scholes option valuation is determined

- using the expected life of the stock option, expected volatility of the Company's common share price, expected dividend yield, and risk-free interest rate.
2. On May 28, 2013 the Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4 of the TSXV), and its NEOs (Messrs. Morgan and Churchill) resigned as directors and officers of the Company.
 3. Mr. Reinhard Gabathuler was appointed as the Company's Chief Executive Officer effective May 28, 2013.
 4. Ms. Judi Dalling was appointed as the Company's Chief Financial Officer and Corporate Secretary effective May 28, 2013.

The Company entered into a consulting agreement with Cydweli Consultants Inc. and Dr. Reinhard Gabathuler for consulting services and for acting in his capacity as President and Chief Executive Officer for a base fee payable of \$60,000 per annum for services rendered. The initial term expired on May 28, 2014, and subject to the automatic applicable renewal clause, has been annually renewed for a further one year for a base fee payable of \$96,000 per annum. The consulting agreement also provides for an annual incentive bonus to be determined by the Board of Directors of the Company.

The Company entered into a consulting agreement with Judi Dalling for consulting services and for acting in her capacity as Chief Financial Officer and Corporate Secretary. The initial term expired on May 28, 2014, and subject to the automatic renewal clause, has been annually renewed for a further one year. The consulting agreement provides for a base fee payable of \$65,000 per annum for services rendered and provides for an annual incentive bonus to be determined by the Board of Directors of the Company.

Incentive Plan Awards – Outstanding Option-based Awards

The following table sets out the stock options (option-based awards) outstanding as at the year ended November 30, 2013 for each of the NEOs. On November 29, 2013, the last trading date the Company's Common Shares were traded on the TSXV prior to November 30, 2013, the closing price of the Company's Common Shares was \$0.28.

Name	Number of securities underlying unexercised options ⁽¹⁾	Option exercise price (\$)	Option expiration date ⁽¹⁾	Value of unexercised in-the-money options (\$)
John Morgan CEO ⁽¹⁾	175,000	0.10	May 28, 2014	31,500
Kenneth Churchill CFO and Corporate Secretary ⁽¹⁾	175,000	0.10	May 28, 2014	31,500
Reinhard Gabathuler President and CEO ⁽²⁾	200,000	0.23	June 19, 2018	10,000
Judi Dalling, CFO and Corporate Secretary ⁽³⁾	175,000	0.23	June 19, 2018	8,750

Notes:

1. On May 28, 2013 the Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4 of the TSXV), and its NEOs (Messrs. Morgan and Churchill) resigned as directors and officers of the Company.
2. Mr. Reinhard Gabathuler was appointed as the Company's chief Executive Officer effective May 28, 2013.
3. Ms. Judi Dalling was appointed as the Company's Chief Financial Officer and Corporate Secretary effective May 28, 2013.

The Company has no share-based compensation arrangements.

Incentive Plan Awards – Value vested or earned during the year

The following table shows the incentive plan awards value vested (or earned) during the year ended November 30, 2013 for each NEO:

Name	Option-based awards – Value vested during the year ⁽¹⁾ (\$)
John Morgan CEO ⁽²⁾	Nil
Kenneth Churchill CFO and Corporate Secretary ⁽²⁾	Nil
Reinhard Gabathuler President and CEO ⁽³⁾	Nil
Judi Dalling, CFO and Corporate Secretary ⁽⁴⁾	Nil

Notes:

1. These amounts represent the aggregate dollar value that would have been realized if the options under the option-based award had been exercised on the vesting date. The value of each amount has been determined by taking the difference between the market price of the shares at the date of exercise and the exercise or base price of the option under the option-based award on the vest date.
2. On May 28, 2013 the Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4 of the TSXV), and its NEOs (Messrs. Morgan and Churchill) resigned as directors and officers of the Company.
3. Mr. Reinhard Gabathuler was appointed as the Company's chief Executive Officer effective May 28, 2013.
4. Ms. Judi Dalling was appointed as the Company's Chief Financial Officer and Corporate Secretary effective May 28, 2013.

All options granted to NEOs have been granted under the Option Plan, the terms of which are described under "Approval of the Stock Option Plan" above.

Pension Plan Benefits

The Company does not have a pension plan, retirement plan or deferred compensation plan.

Termination and Change of Control Benefits

The Company has entered into a consulting agreement with Cydwell Consultants Inc. and Dr. Reinhard Gabathuler for services in his capacity as President and Chief Executive Officer. The Company may terminate the agreement without cause for a lump sum payment of two months of salary. In the event the agreement is terminated within 12 months following the change of control of the Company, a lump sum payment of two months' salary is payable.

The Company has entered into a consulting agreement with Judi Dalling for services in her capacity as Chief Financial Officer. The Company may terminate the agreement without cause for a lump sum payment of two months of salary. In the event the agreement is terminated within 12 months following the change of control of the Company, a lump sum payment of three months' salary is payable.

Director Compensation

The following table sets out, for each director that is not a NEO, compensation earned for the fiscal year ended November 30, 2013:

Name	Fees Earned (\$)	Option-based awards ⁽¹⁾ (\$)	All other compensation (\$)	Total Compensation (\$)
Richard Jordens ⁽²⁾	Nil	Nil	Nil	Nil
Robin Hutchison ⁽³⁾	48,000	38,035	Nil	86,035
J. Michael Hutchison, Q.C. ⁽⁴⁾⁽⁵⁾	Nil	12,641	Nil	12,641
Craig D. Thomas ⁽⁵⁾	Nil	12,641	Nil	12,641
Karoly Nikolich ⁽⁶⁾	Nil	5,462	Nil	5,462

Notes:

- The grant date fair value of these options would have been calculated in accordance with Section 3870 of the CICA Handbook (accounting fair value) using the Black-Scholes model. The Black-Scholes option valuation is determined using the expected life of the stock option, expected volatility of the Company's common share price, expected dividend yield, and risk-free interest rate.
- On May 28, 2013 the Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4 of the TSXV), and Mr. Jordens resigned as a director of the Company.
- Mr. Robin Hutchison was appointed as the company's Executive Chairman effective May 28, 2013.
- During the fiscal year ended November 30, 2013, the Company paid or accrued legal fees of \$11,793.30 to Smith Hutchison Law Corporation, a professional corporation of which J. Michael Hutchison, Q.C., is President.
- Messrs. Craig D. Thomas and Michael Hutchison, QC were appointed as the directors of the Company effective May 28, 2013.
- Mr. Karoly Nikolich was appointed as the Company's director effective September 24, 2013.

Directors Incentive Plan Awards - Outstanding Option-based Awards

The following table sets out, for each director that is not a NEO, the stock options (option-based awards) outstanding as at the year ended November 30, 2013. On November 29, 2013, the last trading date the Company's Common Shares were traded on the TSXV prior to November 30, 2013, the closing price of the Company's Common Shares was \$0.28.

Option-based Awards				
Name	Number of securities underlying unexercised options (#)	Option exercise price (\$)	Option expiration date	Value of unexercised in-the-money options (\$)
Richard Jordens ⁽¹⁾	175,000	0.10	May 28, 2014	31,500
Robin Hutchison	175,000	0.10	May 3, 2017	31,500
	450,000	0.23	June 19, 2018	22,500
J. Michael Hutchison, Q.C. ⁽²⁾	150,000	0.23	June 19, 2018	7,500
Craig D. Thomas ⁽²⁾	150,000	0.23	June 19, 2018	7,500
Karoly Nikolich ⁽³⁾	150,000	0.20	September 23, 2018	12,000

Notes:

- On May 28, 2013 the Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4 of the TSXV), and Mr. Jordens resigned as a director of the Company.
- Messrs. Craig D. Thomas and Michael Hutchison, QC were appointed as the directors of the Company effective May 28, 2013.
- Mr. Karoly Nikolich was appointed as the Company's director effective September 24, 2013.

The Company has no share-based compensation arrangements.

Directors Incentive Plan Awards - Value vested or earned during the year

The following table shows the incentive plan awards value vested (or earned) during the year ended February 28, 2014 for each director that is not a NEO:

Name	Option-based awards – Value vested during the year ⁽¹⁾ (\$)
Richard Jordens ⁽²⁾	Nil
Robin Hutchison	Nil
J. Michael Hutchison, Q.C. ⁽³⁾	Nil
Craig D. Thomas ⁽³⁾	Nil
Karoly Nikolich ⁽⁴⁾	Nil

Notes:

- These amounts represent the aggregate dollar value that would have been realized if the options under the option-based award had been exercised on the vesting date. The value of each amount has been determined by taking the difference between the market price of the shares at the date of exercise and the exercise or base price of the option under the option-based award on the vest date.
- On May 28, 2013 the Company completed its Qualifying Transaction (as such term is defined by the Policy 2.4 of the TSXV), and Mr. Jordens resigned as a director of the Company.
- Messrs. Craig D. Thomas and Michael Hutchison, QC were appointed as the directors of the Company effective May 28, 2013.
- Mr. Karoly Nikolich was appointed as the Company's director effective September 24, 2013.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

The only equity compensation plan which the Company has in place is the existing Option Plan which was previously approved by the TSXV. The Option Plan was established to provide incentive to qualified parties to increase their proprietary interest in the Company and thereby encourage their continued association with the Company. The Option Plan is administered by the Board of Directors and provides that options will be issued to directors, officers, employees, consultants and other Participants (as defined in the Option Plan) of the Company. The Option Plan also provides that the number of Common Shares issuable under the Option Plan, may not exceed 10% of the issued and outstanding Common Shares at any time. All options granted under the Option Plan expire on a date not later than ten years after the date of grant of such option, and are exercisable at an exercise price set by the Board of Directors in its sole discretion which price may not be less than the Discounted Market Price (as defined in the Option Plan). See "Approval of the Stock Option Plan" above for a description of the Option Plan.

As at the end of the most recently completed financial year of the Company ended November 30, 2013 there were 1,825,000 stock options granted or outstanding under the Option Plan.

	Number of securities to be issued upon exercise of outstanding options, warrants and rights as at November 30, 2013	Weighted average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under the Option Plan as at November 30, 2013
Plan Category	(a)	(b)	(c)
Plans approved by security holders	1,825,000	\$0.19	471,500
Plans not approved by security holders	Nil	N/A	Nil
Total	1,825,000	\$0.19	471,500

INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS

None of the directors and officers of the Company, any proposed management nominee for election as a director of the Company or any associate of any director, officer or proposed management nominee is or has been indebted to the Company at any time during the Company's most recently completed financial year.

INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

Except as disclosed in this Circular, no director or officer of the Company, nor any proposed nominee for election as a director of the Company, nor any other insider of the Company, nor any associate or affiliate of any one of them, has any material interest, direct or indirect, in any transaction since the commencement of the Company's most recently completed financial year or in any proposed transaction which, in either case, has or will materially affect the Company and none of such persons has any material interest in any transaction proposed to be undertaken by the Company that will materially affect the Company.

MANAGEMENT CONTRACTS

There are no management functions of the Company, which are to any substantial degree performed by a person or company other than the directors or senior officers of the Company.

CORPORATE GOVERNANCE

Corporate governance is related to the activities of the Board of Directors, the members of which are elected by and are accountable to the shareholders, and takes into account the role of the individual members of management who are appointed by the Board of Directors and who are charged with the day to day management of the Company. The Board of Directors is committed to sound corporate governance practices, which are both in the interest of its shareholders and contribute to effective and efficient decision making.

Pursuant to *National Instrument 58-101 – Disclosure of Corporate Governance Practices* ("NI 58-101"), which came into effect for financial years ending on or after June 30, 2005, the Company is required to disclose its corporate governance practices as summarized below.

Board of Directors

The Board of Directors facilitates its exercising of independent supervision over the Company's management through meetings of the Board of Directors and both directly and indirectly through its committees and independent members. Meetings of the independent directors and committees are not regularly scheduled but communication among this group occurs on an ongoing basis as needs arise from regularly scheduled meetings of the Board of Directors. The number of these informal meetings has not been recorded, but it would not be less than four in the case of the Audit Committee in the fiscal year that ended November 30, 2013. The Board of Directors believes that adequate structures and processes are in place to facilitate the functioning of the Board of Directors with a level of independence of the Company's management.

The Board of Directors currently consists of four directors: Robin Hutchison, J. Michael Hutchison Q.C., Karoly Nikolich and Craig D. Thomas. Messrs. Nikolich and Thomas are independent members of the Board of Directors within the meaning of NI 52-110 in that they are independent and free from an interest, and any business or other relationship which could reasonably be perceived to, materially

interfere with their ability to act with the best interests of the Company, other than interests and relationships arising from shareholders.

The remaining members of the Board of Directors are not considered independent: Mr. Robin Hutchison is an Executive Chairman of the Company and Mr. J. Michael Hutchison, QC is Mr. Robin Hutchison's brother.

Directorships

The following directors, or proposed directors, of the Company are also directors or officers of other reporting issuers (or the equivalent) as set out below:

Name	Name of Reporting Issuer
Robin Hutchison	biOasis Technologies Inc.
Craig D. Thomas	Royal Lifescience Corp. BCM Resources Corporation
J. Michael Hutchison Q.C.	biOasis Technologies Inc.

Board Responsibilities

The Board has overall responsibility for the stewardship of the Company. The Company's Board of Directors is empowered by governing corporate law and the Company's Articles to manage, or supervise the management of, the affairs and business of the Company.

The Board of Directors performs its functions through quarterly and special meetings and has delegated certain of its responsibilities to those committees described below. In addition, the Board of Directors has established policies and procedures that limit the ability of management to carry out certain specific activities without the prior approval of the Board of Directors.

Long-term strategies and annual operating and capital plans with respect to the Company's operations are developed by senior management and reviewed and approved by the Board of Directors.

The Board of Directors, through the Audit Committee, has the responsibility to identify the principal risks of the Company's business. It works with management to implement policies to identify the risks and to establish systems and procedures to ensure that these risks are monitored.

The Board of Directors has delegated responsibility for the integrity of internal controls and management information systems to the Audit Committee. The Company's external auditors report directly to the Audit Committee. In its regular meetings with the external auditors, the Audit Committee discusses, among other things, the Company's financial statements and the adequacy and effectiveness of the Company's internal controls and management information systems.

Orientation and Continuing Education

New directors are briefed on strategic plans, short, medium and long term corporate objectives, business risks and mitigation strategies, corporate governance guidelines and existing company policies. However, there is no formal orientation for new members of the Board, and this is considered to be appropriate, given the Company's size and current level of operations. However, if the growth of the Company's operations warrants it, it is likely that a formal orientation process will be implemented.

Ethical Business Conduct

The Company does not currently have a written code for ethical business conduct.

The Board of Directors encourages and promotes a culture of ethical business conduct by actively overseeing the management of the business. While there is no formal policy on ethical business conduct, the Company carries out its business in accordance with the rules and regulations of all regulatory agencies to which it is subject. This culture of compliance is stressed to all levels of management of the Company to ensure that business is conducted in an ethical and proper manner at all times.

The Company is established under and is therefore governed by the provisions of the *Business Corporations Act* (British Columbia) (the “BCA”). Pursuant to the BCA, a director or officer of the Company must disclose to the Company in writing or by requesting that it be entered in the minutes of meetings of the Board of Directors, the nature and extent of any interest that he or she has in material contract or material transaction, whether made or proposed, with the Company, if the director or officer: (a) is a party to the contract or transaction; (b) is a director or an officer, or an individual acting in a similar capacity, of a party to the contract or transaction; or (c) has a material interest in a party to the contract or transaction. The interested director cannot vote on any resolution to approve such contract or transaction.

Nomination of Directors

The Board of Directors has not appointed a nominating committee. As a result of the Company's size, its stage of development and the limited number of individuals on the Board of Directors, the Board of Directors considers a nominating committee to be inappropriate at this time.

Compensation of Directors and CEO

The Board of Directors does not have a compensation committee or a formal procedure with respect to determining compensation for the Company's directors and CEO. The Company has a consulting agreement with its CEO pursuant to which the CEO receives remuneration for his services. See “*Executive Compensation*” for further details of this agreement. The Board of Directors as a whole is responsible for reviewing the adequacy and form of compensation paid to the Company's executive officers and key employees and ensuring that such compensation realistically reflects the responsibilities and risks of such positions. In fulfilling these responsibilities, the Board of Directors will evaluate the performance of the Company's CEO and other senior management in light of corporate goals and objectives, and will make recommendations with respect to compensation levels based on such evaluation.

Other Committees

The Company does not have any committees other than the Audit Committee. The Board of Directors has determined that additional committees are not necessary at this stage of the Company's development.

Assessments

Neither the Company nor the Board of Directors has determined formal means or methods to regularly assess the Board of Directors, its Committees or individual directors with respect to their effectiveness and contributions. Effectiveness is subjectively measured by comparing actual corporate results with stated objectives. The contributions of an individual director are informally monitored by the other board members, having in mind the business strengths of the individual and the purpose of originally nominating the individual to the Board of Directors.

AUDIT COMMITTEE

National Instrument 52-110 of the Canadian Securities Administrators (“NI 52-110”) requires the Company, as a venture issuer, to disclose annually in its Circular certain information concerning the constitution of its audit committee and its relationship with its independent auditor, set forth as follows:

Audit Committee Charter

The Charter of the Company’s audit committee (the “Audit Committee”) is attached to this Circular as Schedule “A”.

Composition of the Audit Committee

Members of the Audit Committee are: Robin Hutchison, J. Michael Hutchison, QC and Craig D. Thomas. A majority of the members of the Committee are not officers or employees of the Company or of an affiliate of the Company. Two members of the Audit Committee, Messrs. Robin Hutchison (Executive Chairman) and J. Michael Hutchison, QC (sibling of an executive officer) are not independent as defined in NI 52-110. Mr. Craig D. Thomas is an independent member of the Audit Committee. Each member of the Audit Committee is financially literate.

A member of the Audit Committee is *independent* if the member has no director or indirect material relationship with the Company. A material relationship means a relationship which could, in the view of the Board of Directors, reasonably interfere with the exercise of a member’s independent judgment.

A member of the Audit Committee is considered *financially literate* if he or she has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company.

Relevant Education and Experience

Based on their business and educational experiences, each Audit Committee member has a reasonable understanding of the accounting principles used by the Company; an ability to assess the general application of such principles in connection of the accounting for estimates, accruals and reserves; experience analyzing and evaluating financial statements that present a breadth and level of complexity of issues that can reasonably be expected to be raised by the Company’s financial statements, or experience actively supervising one or more individuals engaged in such activities; and an understanding of internal controls and procedures for financial reporting.

Messrs. Robin Hutchison, J. Michael Hutchison, QC and Craig D. Thomas gained financial literacy by serving as directors of a number of the TSXV listed companies.

Audit Committee Oversight

At no time during the Company’s fiscal year ended November 30, 2013 and at no time since the commencement of the Company’s most recently completed financial year were any Audit Committee’s recommendations to nominate or compensate an external auditor not adopted by the Board of Directors.

Reliance on Certain Exemptions

At no time during the Company's fiscal year ended November 30, 2013 and at no time since the commencement of the Company's most recently completed financial year has the Company relied on any exemption under Part 8 of *National Instrument 52-110 – Audit Committees*.

Pre-Approval Policies and Procedures

The Audit Committee has not adopted any specific policies and procedures for the engagement of non-audit services.

External Auditor Service Fees

The aggregate fees billed by the Company's external auditors in each of the last two fiscal years are:

Financial Year/Period Ending	Audit Fees	Audit Related Fees	Tax Fees	All Other Fees
November 30, 2013	\$22,808	Nil	Nil	\$Nil
November 30, 2012	\$29,040	\$Nil	\$Nil	\$Nil

Venture Issuer Exemption

The Company, as a "Venture Issuer", is relying upon section 6.1 of *National Instrument 52-110 – Audit Committees* exempting the Company from certain requirements relating to the composition of the Audit Committee and reporting obligations.

ADDITIONAL INFORMATION

Additional information relating to the Company is included in the Company's audited and consolidated financial statements for the year ended November 30, 2013, the auditor's report thereon and related management discussion and analysis filed on www.sedar.com. Copies of the Company's most current interim financial statements and related management discussion and analysis, and additional information may be obtained from www.sedar.com and upon request from the Company by telephone at (604) 688-6775, or by fax at (604) 688-6995.

OTHER MATTERS

The Board of Directors is not aware of any other matters which it anticipates will come before the Meeting as of the date of mailing of this Circular.

The contents of this Circular and its distribution to shareholders have been approved by the Board.

DATED at Vancouver, British Columbia, October 1, 2014.

BY ORDER OF THE BOARD OF DIRECTORS

“Reinhard Gabathuler”

Reinhard Gabathuler
President and CEO

SCHEDULE "A"**BioMmune Technologies Inc.****AUDIT COMMITTEE CHARTER****MANDATE**

The primary function of the audit committee (the "Committee") of BioMmune Technologies Inc. (the "Company") is to assist the Board of Directors in fulfilling its financial oversight responsibilities by reviewing the financial reports and other financial information provided by the Company to regulatory authorities and shareholders, the Company's systems of internal controls regarding finance and accounting and the Company's auditing, accounting and financial reporting processes. The Committee's primary duties and responsibilities are to:

- Serve as an independent and objective party to monitor the Company's financial reporting and internal control system and review the Company's financial statements.
- Review and appraise the performance of the Company's external auditors (the "Auditor").
- Provide an open avenue of communication among the Company's auditors, management and the Board of Directors.

COMPOSITION, PROCEDURES AND ORGANIZATION

The Committee shall consist of at least three members. Each member must be a director of the Company. A majority of the members of the Committee shall not be officers or employees of the Company or of an affiliate of the Company. At least one (1) member of the Committee shall be financially literate. All members of the Committee who are not financially literate will work towards becoming financially literate to obtain working familiarity with basic finance and accounting practices. For the purposes of this Charter, the term "financially literate" means the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company's financial statements.

The members of the Committee shall be appointed by the Board of Directors at its first meeting following the annual shareholders' meeting. Unless a Chair is elected by the full Board of Directors, the members of the Committee may designate a Chair by a majority vote of the full Committee membership. The Chair shall be financially literate.

The Board of Directors may at any time remove or replace any member of the Committee and may fill any vacancy in the Committee.

MEETINGS OF THE COMMITTEE

Meetings of the Committee shall be scheduled to take place at regular intervals and, in any event, not less frequently than quarterly. Unless all members are present and waive notice, or those absent waive notice before or after a meeting, the Chairman will give the Committee members 24 hours' advance notice of each meeting and the matters to be discussed at such meeting. Notice may be given personally, by telephone, by facsimile or e-mail.

The Auditor shall be given reasonable notice of, and be entitled to attend and speak at, each meeting of the Committee concerning the Company's annual financial statements and, if the Committee determines it to be necessary or appropriate, at any other meeting. On request by the Auditor, the Chair shall call a meeting of the Committee to consider any matter that the Auditor believes should be brought to the attention of the Committee, the Board of Directors or the shareholders of the Company.

At each meeting of the Committee, a quorum shall consist of a majority of members that are not officers or employees of the Company or of an affiliate of the Company. A member may participate in a meeting of the Committee in person or by telephone if all members participating in the meeting, whether in person or by telephone or other communications medium other than telephone are able to communicate with each other and if all members who wish to participate in the meeting agree to such participation.

The Committee may periodically meet separately with each of management and the Auditor to discuss any matters that the Committee or any of these groups believes would be appropriate to discuss privately. In addition, the Committee should meet with the Auditor and management annually to review the Company's financial statements.

The Committee may invite to its meetings any director, any manager of the Company, and any other person whom it deems appropriate to consult in order to carry out its responsibilities.

RESPONSIBILITIES AND DUTIES

To fulfill its responsibilities and duties, the Committee shall:

- (a) Review the Company's financial statements, including any certification, report, opinion, or review rendered by the Auditor, MD&A and any annual and interim earnings press releases before the Company publicly discloses such information.
- (b) Review and satisfy itself that adequate procedures are in place and review the Company's public disclosure of financial information extracted or derived from its financial statements, other than disclosure described in the previous paragraph, and periodically assess the adequacy of those procedures.
- (c) Be directly responsible for overseeing the work by the Auditor (including resolution of disagreements between management and the Auditor regarding financial reporting) engaged for the purpose of preparing or issuing an audit report or performing other audit review services for the Company.
- (d) Require the Auditor to report directly to the Committee.
- (e) Review annually the performance of the Auditor who shall be ultimately accountable to the Board of Directors and the Committee as representatives of the shareholders of the Company.
- (f) Review and discuss with the Auditor any disclosed relationships or services that may impact the objectivity and independence of the Auditor.
- (g) Take, or recommend that the Board of Directors take, appropriate action to oversee the independence of the Auditor.
- (h) Recommend to the Board of Directors the external auditor to be nominated at the annual general meeting for appointment as the Auditor for the ensuing year and the compensation for the Auditors, or, if applicable, the replacement of the Auditor.

- (i) Review and approve the Company's hiring policies regarding partners, employees and former partners and employees of the Auditor and former independent external auditors of the Company.
- (j) Review with management and the Auditor the audit plan for the annual financial statements.
- (k) Review and pre-approve all audit and audit-related services and the fees and other compensation related thereto, and any non-audit services provided by the Auditor. The pre-approval requirement is waived with respect to the provision of non-audit services if:
 - (i) the aggregate amount of all such non-audit services that were not pre-approved is reasonably expected to constitute not more than 5% of the total amount of fees paid by the Company and its subsidiary entities to the Auditor during the fiscal year in which the non-audit services are provided;
 - (ii) such services were not recognized by the Company at the time of the engagement to be non-audit services; and
 - (iii) such services are promptly brought to the attention of the Committee and approved, prior to the completion of the audit, by the Committee or by one or more members of the Committee to whom authority to grant such approvals has been delegated by the Committee.

The Committee may delegate to one or more independent members of the Committee the authority to pre-approve non-audit services in satisfaction of the pre-approval requirement set forth in this section provided the pre-approval of non-audit services by any member to whom authority has been delegated must be presented to the Committee at its first scheduled meeting following such pre-approval.

- (l) In consultation with the Auditor, review with management the integrity of the Company's financial reporting process, both internal and external.
- (m) Consider the Auditor's judgments about the quality and appropriateness of the Company's accounting principles as applied in its financial reporting.
- (n) Consider and approve, if appropriate, changes to the Company's auditing and accounting principles and practices as suggested by the Auditor and management.
- (o) Review significant judgments made by management in the preparation of the financial statements and the view of the Auditor as to the appropriateness of such judgments.
- (p) Following completion of the annual audit, review separately with management and the Auditor any significant difficulties encountered during the course of the audit, including any restrictions on the scope of the work or access to required information.
- (q) Review any significant disagreement among management and the Auditor in connection with the preparation of the financial statements.
- (r) Review with the Auditor and management the extent to which changes and improvements in financial or accounting practices have been implemented.

- (s) Discuss with the Auditor the Auditor's perception of the Company's financial and accounting personnel, any material recommendations which the Auditor may have, the level of co-operation which the Auditor received during the course of their review and the adequacy of their access to records, data or other requested information.
- (t) Review any complaints or concerns about any questionable accounting, internal accounting controls or auditing matters.
- (u) Establish procedures for:
 - (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls, or auditing matters; and
 - (ii) the confidential, anonymous submission by employees of the Company of concerns regarding questionable accounting or auditing matters.
- (v) Perform such other duties as may be assigned to it by the Board of Directors from time to time or as may be required by applicable regulatory authorities or legislation.
- (w) Report regularly and on a timely basis to the Board of Directors on the matters coming before the Committee.
- (x) Review and reassess the adequacy of this Charter annually and recommend any proposed changes to the Board of Directors for approval.

AUTHORITY

The Committee is authorized to:

- to seek any information it requires from any employee of the Company in order to perform its duties;
- to engage, at the Company's expense, independent legal counsel or other professional advisors in any matter within the scope of the role and duties of the Committee under this Charter;
- to set and pay compensation for any advisors engaged by the Committee; and
- to communicate directly with the internal and external auditors of the Company.

This Charter supersedes and replaces all prior charters and other terms of reference pertaining to the Committee.